Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome.

Tefferi, A; Elliott, M A; Steensma, D P; Hook, C C; Dispenzieria, A; Hanson, C A; Schroeder, G; Letendre, L

Tefferi, A; Elliott, M A; Steensma, D P; Hook, C C; Dispenzieria, A; Hanson, C A; Schroeder, G; Letendre, L.

Affiliation

Tefferi A; Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA.

Leuk Res ; 25(2): 183-5, 2001 Feb.

Article in En | MEDLINE | ID: mdl-11166835

Subject(s)

Amifostine/therapeutic use; Erythropoietin/therapeutic use; Myelodysplastic Syndromes/drug therapy; Aged; Amifostine/administration & dosage; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Recombinant Proteins

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Erythropoietin / Amifostine Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Leuk Res Year: 2001 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links